# Treatment of Fabry Nephropathy: A Literature Review

CorpusID: 260999075 - [https://www.semanticscholar.org/paper/51832453c4e73138619b03ddaa72db216ec9d3e2](https://www.semanticscholar.org/paper/51832453c4e73138619b03ddaa72db216ec9d3e2)

Fields: Medicine

## (s6) Chaperon Therapy for Fabry Nephropathy Migalastat
(p6.0) The pharmacological chaperone migalastat was approved by the European Medicines Agency in 2016 and the U.S. Food Drug Administration in 2018 for the treatment of Fabry disease in patients with an eGFR > 30 mL/min and a mutation that is amenable to migalastat.It is estimated that approx.30-50% of individuals with Fabry disease have amenable mutations to migalastat [41].
